bta takeover very possible

Do the numbers at this low Shareprice.

BTA currently approx $35 Million in Bank Cash

GSK owes BTA approx $AU65 million June 30th 2010.

Thats just for the previous years royalties on Relenza alone.

What will future royalities yield before 2014 when patent expires !! ( which doesnt mean GSK stop selling relenza )

Be mean and say $20 million a year. So $80 million for 4 years.( I believe it will be much higher royalties with H274Y resistance becoming widespread in tamiflu and peramvir )

What Laninamivir worth. $100 million upfront and 10% royalties to BTA. Maybe !!!

Whats HRV worth. Cure for the common cold. A multi-billion dollar industry alone in just helping the symptoms.

What IV Relenza worth. Bicryst alone is double BTA capitalization and they only have crappy IV Peramivir.

Add all the other pipeline.


Would GSK pay 175 million shares x $3 for all this.

Think about it.